12:00 AM
Mar 30, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

NT-501: Phase II data

A double-blind, U.S. Phase II trial in 51 patients showed that both doses of NT-501 missed the primary endpoint of an increase in BCVA vs. a sham implant. The high dose of NT-501 stabilized BCVA, as measured by a loss of <15 letters...

Read the full 191 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >